CD19 and neoplasm: Blinatumomab,8 a conjugate of anti‐CD19 and anti‐CD3 monoclonal antibodies, can be used to generate CD19‐targeted bispecific Ab‐armed T cells, which can redirect cytotoxic immunocytes to CD19‐positive tumor cells.